Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics
AC Mita, MM Mita, ST Nawrocki, FJ Giles - Clinical cancer research, 2008 - AACR
Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key
regulator of mitosis and programmed cell death. Initially, survivin was described as an …
regulator of mitosis and programmed cell death. Initially, survivin was described as an …
EGFR as a clinical marker in glioblastomas and other gliomas
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …
Personalized immunotherapy against several neuronal and brain tumors
S Kuttruff-coqui, T Weinschenk, J Fritsche… - US Patent …, 2021 - Google Patents
2014-11-12 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines
LW Macharia, W Muriithi, CP Heming, DK Nyaga… - BMC cancer, 2021 - Springer
Background Glioblastoma is a fatal brain tumour with a poor patient survival outcome.
Hypoxia has been shown to reprogram cells towards a stem cell phenotype associated with …
Hypoxia has been shown to reprogram cells towards a stem cell phenotype associated with …
Targeting apoptosis pathways in glioblastoma
G Eisele, M Weller - Cancer letters, 2013 - Elsevier
The treatment of glioblastoma remains a major challenge for clinicians since these highly
aggressive brain tumors are relatively resistant towards radio-and chemotherapy. The …
aggressive brain tumors are relatively resistant towards radio-and chemotherapy. The …
The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin
MD Siegelin, DE Reuss, A Habel… - Molecular cancer …, 2008 - AACR
Resistance to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL/Apo2L) limits
its potential as a drug for cancer therapy. Here, we report that kaempferol, a bioactive plant …
its potential as a drug for cancer therapy. Here, we report that kaempferol, a bioactive plant …
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo
S Hendruschk, R Wiedemuth, A Aigner… - Neuro …, 2011 - academic.oup.com
Malignant glioma represents the most common primary adult brain tumor in Western
industrialized countries. Despite aggressive treatment modalities, the median survival …
industrialized countries. Despite aggressive treatment modalities, the median survival …
Immunotherapy against several tumors including neuronal and brain tumors
T Weinschenk, O Schoor, C Trautwein, N Hilf… - US Patent …, 2012 - Google Patents
The present invention relates to peptides, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the …
immunotherapeutic methods. In particular, the present invention relates to the …
Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas-an immunohistochemical …
AH Habberstad, S Gulati, SH Torp - Diagnostic pathology, 2011 - Springer
Background Histological malignancy grading of astrocytomas can be challenging despite
criteria given by the World Health Organisation (WHO). Grading is fundamental for optimal …
criteria given by the World Health Organisation (WHO). Grading is fundamental for optimal …
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
T Weinschenk, O Schoor, C Trautwein, N Hilf… - US Patent …, 2014 - Google Patents
The present invention relates to immunotherapeutic peptides and their use in
immunotherapy, in particular the immuno therapy of cancer. The present invention discloses …
immunotherapy, in particular the immuno therapy of cancer. The present invention discloses …